The Economic Burden and Non-Adherence Tuberculosis Treatment in Indonesia: Systematic Review


Until today, Tuberculosis (TB) is still taking part as a world health problem, especially in The South East Asia Region. TB in South East Asia contributes almost 50% of the worldwide burden. Indonesia is one of the regional countries that provide to the statistics, and the World Health Organization (WHO) enlisted it in the 30 High-TBBurden Countries. The high number of TB in Indonesia mostly caused by a lack of case registration, non-adherence of treatment, and lost to follow-up. This study conducted an overview of systematic review based on Prisma Protocol to systematically and objectively focus on the economic burden as a risk factor of non-adherence of TB treatment in Indonesia. Relevant literature was searched from PubMed, Science Direct,
Google Scholar and reviewed abstracts and full-text article based on eligibility criteria. Seven studies included in this review after selected using inclusion and exclusion criteria. The studies revealed a consistent association between economic burden as a risk factor of non-adherence of TB treatment. In conclusion, financial burden was significant with non-adherence of TB treatment and most of TB patient who stopped the treatment should spare their family spending into TB treatment and this often constitutes to more considerable financial risk for them.

Keywords: Tuberculosis, Economic burden, Non-adherence, Indonesia

[1] Kementerian Kesehatan RI Direktorat Jendral Pengendalian Penyakit dan Penyehatan Lingkungan. Information-2016-TB [Internet]. Pusat Data dan Informasi Kementerian Ksehatan RI; 2016. Available from:

[2] Report A. 2 |Bending the Curve - Ending TB. 2017; Available from 10665/254762/1/978929022584-eng.pdf?ua=1

[3] Kartasasmita CB. Epidemiology Tuberculosis. Sari Pediatr [Internet]. 2009;11(2):124–9. Available from:

[4] Aditama TY. Tuberculosis dan Kemiskinan. 2005 Jul;49–51. Available from: index.php?uPage=mki.mki_dl&smod=mki&sp=public&key=OC0z

[5] Hof S Van Den, Collins D, Hafidz F, Beyene D, Tursynbayeva A. The socioeconomic impact of multidrugresistant tuberculosis on patients?: results from Ethiopia, Indonesia and Kazakhstan. BMC Infect Dis
[Internet]. 2016;16:1–14. Available from:

[6] Rutherford ME, Hill PC, Maharani W, Sampurno H, Ruslami R. Risk factors for treatment default among adult tuberculosis patients in Indonesia. Int J Tuberc Lung Dis [Internet]. 2013;17(February):1304–9. Available from:

[7] Laurence Y V, Griffiths UK, Vassall A, Laurence Y V. Costs to Health Services and the Patient of Treating Tuberculosis?: A Systematic Literature Review. Pharmacoeconomics [Internet]. 2015;33(9):939–55. Available from:

[8] Widjanarko B. Factors that influence treatment adherence of tuberculosis patients living in Java, Indonesia. Patient Prefer Adherence [Internet]. 2009;3:231–8. Available from: https://www.ncbi.nlm.nih. gov/pmc/articles/PMC2778426/

[9] Tanimura T, Jaramillo E, Weil D, Raviglione M. Financial burden for tuberculosis patients in low-andmiddle-income countries: a systematic review. Eur Respir J [Internet]. 2014;43:1763–75. Available from:

[10] Munro SA, Lewin SA, Smith HJ, Engel ME, Fretheim A, Volmink J. Patient Adherence to Tuberculosis Treatment?: A Systematic Review of Qualitative Research. PLOS Med [Internet]. 2007;4(7):1230–45. Available from:

[11] Karyadi E, West CE, Nelwan RHH, Dolmans WM V, Meer JWM Van Der, Schultink JW. Social Aspects of Patients with Pulmonary Tuberculosis in Indonesia. Southeast Asian J Trop Med Public Health [Internet]. 2002;33(2):338–45. Available from:

[12] Tiemersma EW, Hafidz F. Costs faced by (multidrug resistant) tuberculosis patients during diagnosis and treatment Report from a pilot study in Indonesia [Internet]. The Hague; 2014. Available from:

[13] Sciences M, Cambridge MD. The Economic Burden of Tuberculosis in Indonesia [Internet]. 2013. Available from: The_Economic_Burden_of_Tuberculosis_in_Indonesia.pdf

[14] In STB. The Economic Impact of Tuberculosis [Internet]. 2000. Available from: assets/documents/events/meetings/amsterdam_conference/ahlburg.pdf

[15] Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses?: the PRISMA statement. 2009;2535( July):1–8. Available from: content/bmj/339/bmj.b2535.full.pdf